

Table 3.2
Verified Outcomes (Annualized Percentages) by Race/Ethnicity for MRC Super Cohort Participants¹

Data as of: February 19, 2022; Events through February 19, 2022

Outcomes	Race/Ethnicity						
	American Indian/ Alaska Native	Asian or Native Hawaiian/ Other Pacific Islander ²	Hispanic/ Latina	Non-Hispanic Black/African American	Non-Hispanic White	More than one Race	Other/ Not Reported
Number randomized	108	526	6525	14025	22278	550	162
Mean follow-up (months)	171.7	182.7	164.8	172.6	207.8	211.6	167.7
Cardiovascular							
CHD ³	8 (0.52%)	36 (0.45%)	288 (0.32%)	1095 (0.54%)	2513 (0.65%)	51 (0.53%)	17 (0.75%)
CHD death ⁴	5 (0.32%)	13 (0.16%)	117 (0.13%)	612 (0.30%)	1133 (0.29%)	27 (0.28%)	11 (0.49%)
Clinical MI	6 (0.39%)	28 (0.35%)	206 (0.23%)	633 (0.31%)	1703 (0.44%)	33 (0.34%)	9 (0.40%)
Angina ⁵	7 (0.85%)	16 (0.39%)	160 (0.33%)	532 (0.49%)	886 (0.49%)	16 (0.35%)	8 (0.67%)
CABG/PTCA	7 (0.45%)	23 (0.29%)	303 (0.34%)	757 (0.38%)	2034 (0.53%)	37 (0.38%)	9 (0.40%)
Carotid artery disease	4 (0.26%)	3 (0.04%)	26 (0.03%)	96 (0.05%)	400 (0.10%)	7 (0.07%)	1 (0.04%)
Congestive heart failure, WHI ⁵	2 (0.24%)	9 (0.22%)	93 (0.19%)	466 (0.43%)	658 (0.36%)	15 (0.33%)	3 (0.25%)
Heart failure, UNC ⁶	9 (0.81%)	22 (0.28%)	205 (0.23%)	862 (2.08%)	2232 (0.59%)	51 (0.90%)	11 (1.02%)
Stroke	7 (0.45%)	22 (0.27%)	270 (0.30%)	950 (0.47%)	2020 (0.52%)	51 (0.53%)	14 (0.62%)
PAD	1 (0.06%)	8 (0.10%)	41 (0.05%)	251 (0.12%)	408 (0.11%)	10 (0.10%)	3 (0.13%)
DVT	5 (0.32%)	2 (0.02%)	88 (0.10%)	381 (0.19%)	932 (0.24%)	18 (0.19%)	6 (0.26%)
Pulmonary embolism	5 (0.32%)	2 (0.02%)	57 (0.06%)	353 (0.17%)	744 (0.19%)	14 (0.14%)	6 (0.26%)
DVT/PE	8 (0.52%)	3 (0.04%)	122 (0.14%)	603 (0.30%)	1328 (0.34%)	27 (0.28%)	9 (0.40%)
Coronary disease ⁷	19 (1.23%)	66 (0.82%)	646 (0.72%)	2287 (1.13%)	4996 (1.30%)	104 (1.07%)	31 (1.37%)
Aortic aneurysm ⁸	0 (0.00%)	2 (0.09%)	5 (0.02%)	19 (0.04%)	50 (0.04%)	3 (0.10%)	0 (0.00%)
Valvular heart disease ⁸	0 (0.00%)	4 (0.19%)	56 (0.24%)	79 (0.15%)	446 (0.38%)	9 (0.31%)	2 (0.32%)
Total cardiovascular disease⁹	24 (1.55%)	94 (1.17%)	923 (1.03%)	3276 (1.62%)	7022 (1.82%)	159 (1.64%)	43 (1.90%)

¹ The MRC Super Cohort includes all WHI Hormone Trial participants and all Non-Hispanic Black/African American and Hispanic/Latina participants from the CT and OS (identified from race/ethnicity collected on Form 2 at baseline. However, race/ethnicity is presented using the imputed Form 41 data and following the WHI Race/Ethnicity Task Force guidelines.

² Native Hawaiian/Other Pacific Islander MRC Super Cohort participants (n=40) are combined with Asian MRC Super Cohort participants for reporting purposes due to small numbers.

³ "CHD" includes clinical MI, evolving Q-wave MI, and CHD death; Q-wave MI is not collected in the WHI Extension Studies 2005-2025.

⁴ "CHD death" includes definite and possible CHD death.

⁵ Angina and CHF are not verified outcomes in the WHI Extension Studies 2005-2025. Reported statistics represent experience during the original program.

⁶ Definite or possible decompensated heart failure adjudicated by UNC.

⁷ "Coronary disease" includes clinical MI, evolving Q-wave MI, possible evolving Q-wave MI, CHD death, angina, congestive heart failure, UNC heart failure, and CABG/PTCA; Q-wave MI, angina and congestive heart failure are not collected in the WHI Extension Studies 2005-2025.

⁸ Aortic aneurysm and valvular heart disease are new adjudicated outcomes during the WHI Extension Study 2010-2025.

⁹ Total CVD does not include aortic aneurysm or valvular heart disease.

Table 3.2 (continued)
Verified Outcomes (Annualized Percentages) by Race/Ethnicity for MRC Super Cohort Participants¹

Data as of: February 19, 2022; Events through February 19, 2022

Outcomes	Race/Ethnicity						
	American Indian/ Alaska Native	Asian or Native Hawaiian/ Other Pacific Islander ²	Hispanic/ Latina	Non-Hispanic Black/African American	Non-Hispanic White	More than one Race	Other/ Not Reported
Number randomized	108	526	6525	14025	22278	550	162
Mean follow-up (months)	171.7	182.7	164.8	172.6	207.8	211.6	167.7
Breast cancer	6 (0.39%)	35 (0.44%)	331 (0.37%)	933 (0.46%)	1741 (0.45%)	40 (0.41%)	8 (0.35%)
Invasive breast cancer	6 (0.39%)	27 (0.34%)	270 (0.30%)	752 (0.37%)	1455 (0.38%)	34 (0.35%)	8 (0.35%)
In situ breast cancer	0 (0.00%)	9 (0.11%)	67 (0.07%)	207 (0.10%)	315 (0.08%)	6 (0.06%)	0 (0.00%)
Ovarian cancer	2 (0.13%)	2 (0.02%)	37 (0.04%)	75 (0.04%)	171 (0.04%)	4 (0.04%)	1 (0.04%)
Endometrial cancer ³	2 (0.25%)	2 (0.04%)	33 (0.07%)	91 (0.10%)	221 (0.09%)	1 (0.02%)	1 (0.08%)
Colorectal cancer	1 (0.06%)	14 (0.17%)	86 (0.10%)	300 (0.15%)	582 (0.15%)	18 (0.19%)	4 (0.18%)
Other cancer ⁴	14 (0.91%)	52 (0.65%)	398 (0.44%)	1120 (0.56%)	2913 (0.76%)	53 (0.55%)	11 (0.49%)
Total cancer	23 (1.49%)	99 (1.24%)	824 (0.92%)	2326 (1.15%)	5174 (1.34%)	108 (1.11%)	24 (1.06%)
Fractures							
Hip fracture	3 (0.19%)	12 (0.15%)	89 (0.10%)	146 (0.07%)	1536 (0.40%)	23 (0.24%)	4 (0.18%)
Deaths							
Cardiovascular deaths	7 (0.45%)	29 (0.36%)	293 (0.33%)	1302 (0.65%)	2797 (0.73%)	52 (0.54%)	18 (0.79%)
Cancer deaths	9 (0.58%)	37 (0.46%)	326 (0.36%)	996 (0.49%)	2072 (0.54%)	41 (0.42%)	13 (0.57%)
Other known cause	15 (0.97%)	35 (0.44%)	361 (0.40%)	1074 (0.53%)	3107 (0.81%)	62 (0.64%)	14 (0.62%)
Unknown cause	0 (0.00%)	2 (0.02%)	16 (0.02%)	28 (0.01%)	60 (0.02%)	0 (0.00%)	1 (0.04%)
Not yet adjudicated	4 (0.26%)	2 (0.02%)	35 (0.04%)	102 (0.05%)	257 (0.07%)	8 (0.08%)	2 (0.09%)
Total death⁵	56 (2.60%)	213 (1.94%)	2194 (1.56%)	6514 (2.29%)	11925 (2.63%)	263 (2.24%)	71 (2.21%)

¹ The MRC Super Cohort includes all WHI Hormone Trial participants and all Non-Hispanic Black/African American and Hispanic/Latina participants from the CT and OS (identified from race/ethnicity collected on Form 2 at baseline. However, race/ethnicity is presented using the imputed Form 41 data and following the WHI Race/Ethnicity Task Force guidelines.

² Native Hawaiian/Other Pacific Islander MRC Super Cohort participants (n=40) are combined with Asian MRC Super Cohort participants for reporting purposes due to small numbers.

³ Only women without a baseline hysterectomy are used to compute the annual rates of endometrial cancer.

⁴ Only one report of "other cancer" is counted per woman; however, the first of each type is adjudicated. Excludes non-melanoma skin cancer.

⁵ Includes deaths for non-Extension study participants after the main WHI study close-out. Annualized rates incorporate additional follow-up from the NDI search.